Platinum-refractory germ cell tumors: an update on current treatment options and developments

Platinum-refractory germ cell tumors: an update on current treatment options and developments World J Urol (2017) 35:1167–1175 DOI 10.1007/s00345-016-1898-z TOPIC PAPER Platinum‑refractory germ cell tumors: an update on current treatment options and developments 1 1 1 1 Christoph Oing · Winfried H. Alsdorf · Gunhild von Amsberg · Karin Oechsle · Carsten Bokemeyer Received: 11 November 2015 / Accepted: 13 July 2016 / Published online: 23 July 2016 © Springer-Verlag Berlin Heidelberg 2016 Abstract and long-term survival in approximately 10–15 %. To Purpose In general, 50 % up to 80 % of metastasized germ date, no molecularly targeted agent has shown reasonable cell tumor patients can be cured by platinum-based chemo- activity. therapy. However, 3–5 % of patients will still die of plati- Conclusions Treatment options for platinum-refractory num-refractory disease and new systemic treatment options disease are limited, but a small subset of patients may are needed to improve treatment success in this difficult achieve long-term disease-free survival by multimodal setting. This review aims to give an overview on treatment treatment. The potential of novel targeted agents, i.e. by options and current developments in the field of platinum- immune-checkpoint-inhibition remains to be defined. refractory male germ cell tumors. Methods A comprehensive literature search was conducted Keywords Germ cell tumor · Germ http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png World Journal of Urology Springer Journals

Platinum-refractory germ cell tumors: an update on current treatment options and developments

Loading next page...
 
/lp/springer_journal/platinum-refractory-germ-cell-tumors-an-update-on-current-treatment-E41ARZuQ0P
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2016 by Springer-Verlag Berlin Heidelberg
Subject
Medicine & Public Health; Urology; Nephrology; Oncology
ISSN
0724-4983
eISSN
1433-8726
D.O.I.
10.1007/s00345-016-1898-z
Publisher site
See Article on Publisher Site

Abstract

World J Urol (2017) 35:1167–1175 DOI 10.1007/s00345-016-1898-z TOPIC PAPER Platinum‑refractory germ cell tumors: an update on current treatment options and developments 1 1 1 1 Christoph Oing · Winfried H. Alsdorf · Gunhild von Amsberg · Karin Oechsle · Carsten Bokemeyer Received: 11 November 2015 / Accepted: 13 July 2016 / Published online: 23 July 2016 © Springer-Verlag Berlin Heidelberg 2016 Abstract and long-term survival in approximately 10–15 %. To Purpose In general, 50 % up to 80 % of metastasized germ date, no molecularly targeted agent has shown reasonable cell tumor patients can be cured by platinum-based chemo- activity. therapy. However, 3–5 % of patients will still die of plati- Conclusions Treatment options for platinum-refractory num-refractory disease and new systemic treatment options disease are limited, but a small subset of patients may are needed to improve treatment success in this difficult achieve long-term disease-free survival by multimodal setting. This review aims to give an overview on treatment treatment. The potential of novel targeted agents, i.e. by options and current developments in the field of platinum- immune-checkpoint-inhibition remains to be defined. refractory male germ cell tumors. Methods A comprehensive literature search was conducted Keywords Germ cell tumor · Germ

Journal

World Journal of UrologySpringer Journals

Published: Jul 23, 2016

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off